{"analyses":[{"ciLowerLimit":"-13.64","ciPctValue":"95","ciUpperLimit":"-5.99","estimateComment":"Afatinib 40 mg-Pemetrexed/Cisplatin Chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Mean Difference (Final Values)","paramValue":"-9.82","statisticalComment":"Adjusted for baseline SoD, EGFR mutation group and race.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.12","value":"33.19"},{"groupId":"OG001","spread":"1.59","value":"43.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"description":"Tumour shrinkage was calculated as the minimum Sum of Diameters (SoD) of target lesions from all post-baseline tumour assessments, as read by the central independent review. The mean of these minimum values were presented after adjusting for baseline SoD, EGFR mutation group and race.","dispersionType":"Standard Error","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"MEAN","populationDescription":"RS. There were only 203 patients in the Afatinib 40 mg arm and 101 patients in the Pemetrexed/Cisplatin Chemotherapy with tumour measurements.","reportingStatus":"POSTED","timeFrame":"Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression","title":"Tumour Shrinkage","type":"SECONDARY","unitOfMeasure":"mm."}